Phospholipase A2 products predict the hematopoietic support capacity of horse serum.

This research article investigates the factors that influence the effectiveness of horse serum in supporting the growth of hematopoietic progenitor cells. The scientists discover that specific byproducts of an enzyme known as phospholipase A2 are linked to the efficacy of the horse serum, and propose this as a standard for evaluating the quality of sera.

Main Findings of the Study

• The study found that the horse serum’s capacity to support the growth of murine hematopoietic progenitor FDCP-Mix cells, which are cells that give rise to various types of blood cells, is associated with the concentration of specific fatty acid products produced by the enzyme phospholipase A2.
• This correlation extended even further to the range of eicosanoids generated by further processing these products through two other enzymes, cyclooxygenase and lipoxygenase. Eicosanoids are signaling molecules made by the oxidation of 20-carbon fatty acids.
• It was identified that sera capable of successful cell support had low levels of lysophosphatidylcholine and inflammatory eicosanoids.

Implications of the Study

• This discovery connects established markers of inflammation, infection, and platelet activation to the horse serum’s ability to preserve progenitor cells in an undifferentiated state. This is a significant finding as it means these markers can potentially be utilized to predict the effectiveness of the serum in supporting cell growth.
• Being able to prospectively identify suitable sera would streamline the process of maintaining these cells in culture as it would eliminate the need for extensive parallel testing of multiple batches over long periods.
• Furthermore, this discovery provides a means of quality control for the horse serum production process, potentially making it more reliable and efficient.